Document Classification

Section Type: RESULTS

Text: At week 52, 41. 8 % of patients who continued to receive vedolizumab every 8 weeks and 44. 8 % of patients who continued to receive vedolizumab every 4 weeks were in clinical remission (Mayo Clinic score 2 and no subscore > 1), as compared with 15. 9 % of patients who switched to placebo (adjusted difference, 26. 1 percentage points for vedolizumab every 8 weeks vs. placebo [95 % CI, 14. 9 to 37. 2 ; P < 0. 001] and 29. 1 percentage points for vedolizumab every 4 weeks vs. placebo [95 % CI, 17. 9 to 40. 4 ; P < 0. 001]).